The Pancreatic Cancer Action Network (PanCAN), the leading nonprofit organization dedicated to [...] READ MORE ...

We're the national organization providing support, resources, volunteer opportunities and hope for people fighting pancreatic cancer.

Editor’s Note: PanCAN volunteers devote their time, energy and passion year-round to improving the lives of everyone impacted by pancreatic cancer. To celebrate Volunteer Appreciation Week 2025 (April ...

The U.S Food & Drug Administration has granted approval for a targeted therapy called CABOMETYX ® to treat pancreatic neuroendocrine tumors, also called PNET or PanNET.

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit outlines the latest advances in pancreatic cancer and offers key insights from ASCO GI 2025.

Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and New Treatments for Patients LOS ANGELES, Calif. – (January 16, 2025) – After ...

In a Phase III clinical trial, a therapy known as Tumor Treating Fields (TTFields) increased survival for patients whose pancreatic cancer had not spread to other organs but cannot be removed by ...

En celebración del Mes Nacional de la Herencia Hispana, disfrute de deliciosas recetas con un toque latino de una manera más saludable para reducir las calorías y el colesterol.

Anna Berkenblit, MD, MMSc, is looking forward to bringing her dual experience as a clinician and biotech executive to her new role as PanCAN’s Chief Scientific and Medical Officer.

For the first time in more than 10 years, the FDA has approved a new first-line treatment, called NALIRIFOX, for patients with metastatic pancreatic cancer.

For the third year in the row, the pancreatic cancer five-year survival rate has increased one percentage point, to 13%, according to the American Cancer Society’s Cancer Facts & Figures 2024 Report.

Despite advances in pancreatic cancer the disease is on track to become the second-leading cause of cancer-related deaths before 2030 LOS ANGELES, Calif. – (January 17, 2024) – The five-year survival ...